Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection

Autor: Nicolai Juul Birkbak, Morten Lundh, Christopher T. Workman, Steven Paraskevas, Susanne Mandrup, Søren Fisker Schmidt, Reid Aikin, Lykke Blaabjerg, Lars Groth Grunnet, Daniel Noesgaard, Dan Ploug Christensen, Paolo Mascagni, Gianluca Fossati, Conny Gysemans, Chantal Mathieu, Thomas Mandrup-Poulsen, Nils Billestrup, Mattias S. Dahllöf, Valmen Monzani, Lorenzo Piemonti, Charles A. Dinarello

Publikováno v: Christensen, D P, Gysemans, C, Lundh, M, Dahllöf, M S, Noesgaard, D, Schmidt, S F, Mandrup, S, Birkbak, N, Workman, C, Piemonti, L, Blaabjerg, L, Monzani, V, Fossati, G, Mascagni, P, Paraskevas, S, Aikin, R A, Billestrup, N, Grunnet, L G, Dinarello, C A, Mathieu, C & Mandrup-Poulsen, T 2014, ' Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection ', Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 3, pp. 1055-9 . https://doi.org/10.1073/pnas.1320850111
Proceedings of the National Academy of Sciences USA, 111, 1055-9
Proceedings of the National Academy of Sciences USA, 111, 3, pp. 1055-9

Type 1 diabetes is due to destruction of pancreatic β-cells. Lysine deacetylase inhibitors (KDACi) protect β-cells from inflammatory destruction in vitro and are promising immunomodulators. Here we demonstrate that the clinically well-tolerated KDA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e178acbef1a94c9140cc523ffbad3fd
https://hdl.handle.net/20.500.14017/46c8e1ed-c60c-4e1d-9bc2-1e66acc3ab5e